New drug aims to slow kidney disease in IgA nephropathy patients

NCT ID NCT07354932

Recruiting now Disease control Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests an investigational drug called SHR-2173 in 84 adults with primary IgA nephropathy, a kidney disease. Participants receive either a high, medium, or low dose of SHR-2173 or a placebo for 48 weeks. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-2173 injection
What this could lead to: If successful, this could point toward a new treatment option to control IgA nephropathy and reduce kidney damage.
What could go wrong: This is an early Phase 2 trial with only 84 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IGA NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IGA NEPHROPATHY

Contacts and locations

Locations

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China
The First Affiliated Hospital of Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.